BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2023 8:11:23 AM | Browse: 618 | Download: 1442
 |
Received |
|
2023-05-29 08:40 |
|
Peer-Review Started |
|
2023-05-29 08:42 |
|
First Decision by Editorial Office Director |
|
2023-06-20 03:47 |
|
Return for Revision |
|
2023-06-20 03:47 |
|
Revised |
|
2023-07-22 14:04 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-08-14 02:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-08-15 09:25 |
|
Articles in Press |
|
2023-08-15 09:25 |
|
Edit the Manuscript by Language Editor |
|
2023-08-10 00:05 |
|
Typeset the Manuscript |
|
2023-08-21 08:01 |
|
Publish the Manuscript Online |
|
2023-09-01 08:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung and Man Fai Law |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Man Fai Law, MRCP, Doctor, Doctor, Department of Medicine and Therapeutics, Prince of Wales Hospital, 30-32 Ngai Shing Street, Shatin, Hong Kong 852, China. mflaw99@yahoo.com.hk |
| Key Words |
Hepatitis B; Hematologic neoplasms; Chimeric antigen receptor-T cell therapy; Monoclonal antibodies; Bruton’s tyrosine kinase inhibitors; Antiviral agents |
| Core Tip |
Patients with chronic or past resolved hepatitis B virus (HBV) infection are at risk of reactivation of the virus when they receive chemotherapy or immunosuppressive therapy. Therefore, before treatment, patients should be screened for HBV markers, specifically hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen. Prophylactic antiviral therapy is important for HBsAg-positive patients, and is a reasonable option for patients with resolved HBV infection who are scheduled to receive high-risk therapy such as anti-CD20 monoclonal antibodies, anti-CD79 monoclonal antibodies, bispecific antibodies, chimeric antigen receptor-T cell therapy, or hematopoietic stem cell transplantation. For other patients with resolved HBV infection, pre-emptive antiviral therapy guided by serial monitoring of HBV DNA is a reasonable option. |
| Publish Date |
2023-09-01 08:11 |
| Citation |
Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i33/4942.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i33.4942 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
